SURGERY PARTNERS INC (SGRY) Fundamental Analysis & Valuation
NASDAQ:SGRY • US86881A1007
Current stock price
12.3 USD
+0.12 (+0.99%)
At close:
12.3 USD
0 (0%)
After Hours:
This SGRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SGRY Profitability Analysis
1.1 Basic Checks
- In the past year SGRY was profitable.
- SGRY had a positive operating cash flow in the past year.
- SGRY had negative earnings in each of the past 5 years.
- In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
- SGRY has a Return On Assets of -0.96%. This is comparable to the rest of the industry: SGRY outperforms 42.00% of its industry peers.
- Looking at the Return On Equity, with a value of -4.55%, SGRY is in line with its industry, outperforming 48.00% of the companies in the same industry.
- SGRY has a Return On Invested Capital (5.05%) which is in line with its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 8.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.96% | ||
| ROE | -4.55% | ||
| ROIC | 5.05% |
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
1.3 Margins
- SGRY has a Operating Margin of 14.49%. This is amongst the best in the industry. SGRY outperforms 88.00% of its industry peers.
- In the last couple of years the Operating Margin of SGRY has grown nicely.
- With a Gross Margin value of 25.78%, SGRY perfoms like the industry average, outperforming 55.00% of the companies in the same industry.
- SGRY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.49% | ||
| PM (TTM) | N/A | ||
| GM | 25.78% |
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
2. SGRY Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
- SGRY has more shares outstanding than it did 1 year ago.
- SGRY has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for SGRY is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 0.69, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of 0.69, SGRY is not doing good in the industry: 72.00% of the companies in the same industry are doing better.
- The Debt to FCF ratio of SGRY is 18.93, which is on the high side as it means it would take SGRY, 18.93 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 18.93, SGRY is doing worse than 64.00% of the companies in the same industry.
- SGRY has a Debt/Equity ratio of 2.10. This is a high value indicating a heavy dependency on external financing.
- SGRY has a worse Debt to Equity ratio (2.10) than 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.1 | ||
| Debt/FCF | 18.93 | ||
| Altman-Z | 0.69 |
ROIC/WACC0.57
WACC8.91%
2.3 Liquidity
- A Current Ratio of 1.87 indicates that SGRY should not have too much problems paying its short term obligations.
- The Current ratio of SGRY (1.87) is better than 79.00% of its industry peers.
- SGRY has a Quick Ratio of 1.71. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
- With a decent Quick ratio value of 1.71, SGRY is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.71 |
3. SGRY Growth Analysis
3.1 Past
- SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.06%.
- The Earnings Per Share has been growing by 52.38% on average over the past years. This is a very strong growth
- SGRY shows a small growth in Revenue. In the last year, the Revenue has grown by 6.24%.
- Measured over the past years, SGRY shows a quite strong growth in Revenue. The Revenue has been growing by 12.21% on average per year.
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
3.2 Future
- SGRY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.13% yearly.
- Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 8.14% on average per year.
EPS Next Y62.98%
EPS Next 2Y44.95%
EPS Next 3Y42.68%
EPS Next 5Y39.13%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.14%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. SGRY Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 26.74, SGRY can be considered very expensive at the moment.
- The rest of the industry has a similar Price/Earnings ratio as SGRY.
- The average S&P500 Price/Earnings ratio is at 26.21. SGRY is around the same levels.
- SGRY is valuated correctly with a Price/Forward Earnings ratio of 16.41.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 68.00% of the companies listed in the same industry.
- SGRY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 16.41 |
4.2 Price Multiples
- 81.00% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of SGRY indicates a rather cheap valuation: SGRY is cheaper than 85.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.14 | ||
| EV/EBITDA | 7.69 |
4.3 Compensation for Growth
- SGRY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- SGRY's earnings are expected to grow with 42.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y44.95%
EPS Next 3Y42.68%
5. SGRY Dividend Analysis
5.1 Amount
- SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SGRY Fundamentals: All Metrics, Ratios and Statistics
12.3
+0.12 (+0.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02 2026-03-02/amc
Earnings (Next)05-11 2026-05-11/bmo
Inst Owners82.8%
Inst Owner Change0%
Ins Owners1.17%
Ins Owner Change1.19%
Market Cap1.59B
Revenue(TTM)3.31B
Net Income(TTM)-77.90M
Analysts81.11
Price Target19.73 (60.41%)
Short Float %17.45%
Short Ratio7.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.91%
Min EPS beat(2)-60.78%
Max EPS beat(2)-23.03%
EPS beat(4)1
Avg EPS beat(4)-21%
Min EPS beat(4)-60.78%
Max EPS beat(4)24.15%
EPS beat(8)4
Avg EPS beat(8)-6.88%
EPS beat(12)8
Avg EPS beat(12)176.88%
EPS beat(16)9
Avg EPS beat(16)102.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.14%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)-24.02%
PT rev (3m)-25.61%
EPS NQ rev (1m)-519.28%
EPS NQ rev (3m)-519.28%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.91%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-4.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 16.41 | ||
| P/S | 0.48 | ||
| P/FCF | 8.14 | ||
| P/OCF | 5.8 | ||
| P/B | 0.93 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.69 |
EPS(TTM)0.46
EY3.74%
EPS(NY)0.75
Fwd EY6.1%
FCF(TTM)1.51
FCFY12.29%
OCF(TTM)2.12
OCFY17.23%
SpS25.57
BVpS13.24
TBVpS-27.22
PEG (NY)0.42
PEG (5Y)N/A
Graham Number11.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.96% | ||
| ROE | -4.55% | ||
| ROCE | 6.39% | ||
| ROIC | 5.05% | ||
| ROICexc | 5.21% | ||
| ROICexgc | 18.67% | ||
| OM | 14.49% | ||
| PM (TTM) | N/A | ||
| GM | 25.78% | ||
| FCFM | 5.91% |
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
ROICexc(3y)5.3%
ROICexc(5y)5.11%
ROICexgc(3y)19.01%
ROICexgc(5y)18.72%
ROCE(3y)6.48%
ROCE(5y)6.19%
ROICexgc growth 3Y2.9%
ROICexgc growth 5Y5.08%
ROICexc growth 3Y1.35%
ROICexc growth 5Y9.67%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
F-Score5
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.1 | ||
| Debt/FCF | 18.93 | ||
| Debt/EBITDA | 5.5 | ||
| Cap/Depr | 44.72% | ||
| Cap/Sales | 2.38% | ||
| Interest Coverage | 1.87 | ||
| Cash Conversion | 41.85% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 0.69 |
F-Score5
WACC8.91%
ROIC/WACC0.57
Cap/Depr(3y)59.72%
Cap/Depr(5y)61.53%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y62.98%
EPS Next 2Y44.95%
EPS Next 3Y42.68%
EPS Next 5Y39.13%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.14%
EBIT growth 1Y1.03%
EBIT growth 3Y8.59%
EBIT growth 5Y20.49%
EBIT Next Year41.41%
EBIT Next 3Y18.21%
EBIT Next 5YN/A
FCF growth 1Y-6.72%
FCF growth 3Y35.74%
FCF growth 5Y-0.84%
OCF growth 1Y-8.6%
OCF growth 3Y19.98%
OCF growth 5Y2.13%
SURGERY PARTNERS INC / SGRY Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 4 / 10 to SGRY.
What is the valuation status for SGRY stock?
ChartMill assigns a valuation rating of 6 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
Can you provide the profitability details for SURGERY PARTNERS INC?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
What is the valuation of SURGERY PARTNERS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 26.74 and the Price/Book (PB) ratio is 0.93.
Can you provide the expected EPS growth for SGRY stock?
The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to grow by 62.98% in the next year.